TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21715446

Group type: EXPERIMENTAL
Intervention: BNP-guided heart failure treatment
Number of subjects: 279

Group type: COMPARATOR
Intervention: Conventional heart failure treatment
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: BNP-guided heart failure treatment (responders)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: BNP-guided heart failure treatment (non-responders)
Number of subjects: 279
Study: 19481203

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 127

Group type: COMPARATOR
Intervention: Labor epidural (EPI) analgesia
Number of subjects: 127
Study: 17056369

Group type: EXPERIMENTAL
Intervention: Clear intraocular lens (VA60BB, HOYA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Yellow intraocular lens (YA60BB, HOYA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (14 cataractous eyes)
Number of subjects: 26
Study: 12762426

Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 102

Group type: COMPARATOR
Intervention: EUSOL
Number of subjects: 102
Study: 11385064

Group type: COMPARATOR
Intervention: Step II diet (25% fat, 7% saturated fatty acids)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil diet (35% fat, 7% saturated fatty acids)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Average American diet (35% fat, 15% saturated fatty acids)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peanut oil diet (35% fat, 7% saturated fatty acids)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peanuts plus peanut butter diet (35% fat, 8% saturated fatty acids)
Number of subjects: 20
Study: 9054281

Group type: EXPERIMENTAL
Intervention: One drink per day
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Less than one drink per week
Number of subjects: 22071
Study: 7969237

Group type: EXPERIMENTAL
Intervention: Direct response to acetylcholine (ACh) stimulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Indirect response via axon reflexes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Counting sweat droplets by computerized scanning
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Direct response
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Droplet number counts of the direct response
Number of subjects: 64
Study: 3573243

Group type: EXPERIMENTAL
Intervention: Tutors offered a short course in critical appraisal of clinical articles
Number of subjects: 4

Group type: COMPARATOR
Intervention: No special intervention (control)
Number of subjects: 4
Study: 2804250

Group type: EXPERIMENTAL
Intervention: Methylprednisolone phosphate (doses between 16 and 1000 mg)
Number of subjects: 6
Study: 31308191

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (8-week course, including two therapy sessions with MDMA)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 7
Study: 28451748

Group type: EXPERIMENTAL
Intervention: BFR-LLRT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LLRT
Number of subjects: 22

Group type: COMPARATOR
Intervention: CTR
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 22
Study: 25861737

Group type: EXPERIMENTAL
Intervention: BI 671800 50 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 671800 200 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 671800 400 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone 220 μg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg qd
Number of subjects: 0
Study: 23471101

Group type: EXPERIMENTAL
Intervention: Niccine 40 μg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 21660523

Group type: EXPERIMENTAL
Intervention: Topical application of tranexamic acid (2.5 g in 250 ml normal saline)
Number of subjects: 100
Study: 18255098

Group type: EXPERIMENTAL
Intervention: Mifepristone (600mg/day for 7 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16617856

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study: 15867406

Group type: EXPERIMENTAL
Intervention: Advanced lipoprotein testing using vertical‐spin density‐gradient ultracentrifugation
Number of subjects: 311

Group type: COMPARATOR
Intervention: Traditional lipoprotein testing using enzymatic methods
Number of subjects: 311
Study: 11280365

Group type: EXPERIMENTAL
Intervention: Bone grafting and implant placement (graft group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Modified implant placement with no bone grafting (trial group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Optimized complete dentures (no‐implant group)
Number of subjects: 43
Study: 9594320

Group type: EXPERIMENTAL
Intervention: Low dose urokinase (22,000 IU/kg, total dose not lower than 1.2 million IU)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: High dose urokinase (30,000 IU/kg, total dose not more than 2.4 million IU)
Number of subjects: 1023
Study: 7892972

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV) with isoflurane 0.97%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled ventilation (IPPV) with isoflurane 0.60%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both SV and IPPV
Number of subjects: 0
Study: 3299177

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29882671

Group type: EXPERIMENTAL
Intervention: Microbot with 4.5 μm magnetic microbead under low gradient magnetic field
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Microbot with 2 μm magnetic microbead under low gradient magnetic field
Number of subjects: 2

Group type: COMPARATOR
Intervention: Microbot in absence of magnetic field
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Microbot under influence of low gradient magnetic field
Number of subjects: 2
Study: 27480103

Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) plus vemurafenib (960 mg twice daily)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo plus vemurafenib (960 mg twice daily)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Cobimetinib plus vemurafenib
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo plus vemurafenib
Number of subjects: 495
Study: 24740547

Group type: EXPERIMENTAL
Intervention: HPV vaccine (specific dosage and duration not mentioned)
Number of subjects: 6051
Study: 22116411

Group type: EXPERIMENTAL
Intervention: Better baseline executive control (Trails B)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Better visual memory performance (Benton visual retention)
Number of subjects: 31
Study: 20093351

Group type: EXPERIMENTAL
Intervention: ECisF (epirubicin 60 mg/m², cisplatin 60 mg/m², 5-FU 200 mg/m² by daily 24-h infusion)
Number of subjects: 349

Group type: COMPARATOR
Intervention: FEC (5-FU 600 mg/m², epirubicin 60 mg/m², cyclophosphamide 600 mg/m²)
Number of subjects: 349
Study: 18505852

Group type: EXPERIMENTAL
Intervention: 25 mg TMC207
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 100 mg TMC207
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 400 mg TMC207
Number of subjects: 75

Group type: COMPARATOR
Intervention: 300 mg isoniazid (INH)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 600 mg rifampin (RIF)
Number of subjects: 75
Study: 15920220

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg orally the evening before surgery and 4 mg IV 15 min before subarachnoid anesthesia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 54
Study: 12933457

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at 0.05, 0.1, or 0.2 mmol/kg of body weight
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at 0.1 mmol/kg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine at 0.1 mmol/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at 0.05 and 0.2 mmol/kg
Number of subjects: 189
Study: 11376235

Group type: EXPERIMENTAL
Intervention: Contact group (received at least four letters per year for five years)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control group (received no further contact)
Number of subjects: 843
Study: 9426097

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8115316

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg daily for 1 month)
Number of subjects: 20
Study: 2960694

Group type: EXPERIMENTAL
Intervention: Thromboxane receptor antagonist BM 13.177 and thromboxane synthase inhibitor dazoxiben
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 25
Study: 30256656

Group type: EXPERIMENTAL
Intervention: Average prenatal carbon monoxide exposure (per 1 ppm increase)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Average prenatal carbon monoxide exposure (per 1 ppm increase) in girls
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Increased respiratory rate at age 30 days
Number of subjects: 384
Study: 27532367

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 75
Study: 25577464

Group type: EXPERIMENTAL
Intervention: Laparoscopic excision of ovarian endometrioma (first surgery group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laparoscopic excision of ovarian endometrioma (recurrent surgery group)
Number of subjects: 28
Study: 24083811

Group type: EXPERIMENTAL
Intervention: New brochure
Number of subjects: 346

Group type: COMPARATOR
Intervention: Old brochure
Number of subjects: 346
Study: 21118410

Group type: EXPERIMENTAL
Intervention: Dual non‐parenteral combination therapy (including bosentan, sitaxentan, ambrisentan, iloprost, and sildenafil)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dual non‐parenteral combination therapy
Number of subjects: 112
Study: 19693799

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trimethoprim 200 mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paliperidone ER with trimethoprim
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 30
Study: 17215422

Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 6
Study: 15129943

Group type: EXPERIMENTAL
Intervention: Starplasty tracheotomy (SPT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Regular tracheotomy (RT)
Number of subjects: 11
Study: 11281672

Group type: EXPERIMENTAL
Intervention: Porcine dermal collagen xenograft (Permacol)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Trapeziectomy alone (control)
Number of subjects: 26
Study: 9755355

Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (e.g., selective serotonin reuptake inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noradrenergic and mixed serotonergic/noradrenergic tricyclic antidepressants
Number of subjects: 0
Study: 8050803

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate with zero ultrafiltration (group II)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetate dialysate with standard ultrafiltration (group I)
Number of subjects: 16
Study: 2656781

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31768724

Group type: EXPERIMENTAL
Intervention: Training with laparoscopic hysterectomy module on a virtual reality simulator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 20
Study: 31444318

Group type: EXPERIMENTAL
Intervention: Pathfile (PF) 1 and PF2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pathfile (PF2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Proglider (PG)
Number of subjects: 36
Study: 28485007

Group type: EXPERIMENTAL
Intervention: Ixazomib plus lenalidomide and dexamethasone (IRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus lenalidomide and dexamethasone (placebo-Rd)
Number of subjects: 0
Study: 26237826

Group type: EXPERIMENTAL
Intervention: Modified dachengqi tang (DCQT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 23522373

Group type: EXPERIMENTAL
Intervention: Perturbation training added to standard care (prevention exercises, quadriceps strengthening, and agility exercises)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (prevention exercises, quadriceps strengthening, and agility exercises)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perturbation training added to standard care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 21620467

Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 5 days
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Ceftriaxone for 10 days
Number of subjects: 1004
Study: 19551680

Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation (MP) after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation (MP) concomitant with intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Only intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison of VA between control and study groups
Number of subjects: 49
Study: 16619152

Group type: EXPERIMENTAL
Intervention: Lipid-associated amphotericin B plus Mycograb
Number of subjects: 139

Group type: COMPARATOR
Intervention: Amphotericin B plus placebo
Number of subjects: 139
Study: 15127870

Group type: EXPERIMENTAL
Intervention: Systematic reviews with direct clinical relevance
Number of subjects: 96
Study: 11229943

Group type: EXPERIMENTAL
Intervention: LET (lidocaine, epinephrine, tetracaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMLA (eutectic mixture of local anesthetics)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LET
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 60
Study: 9390596

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 2.5 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 5 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 10 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups receiving opioids
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 8578350

Group type: EXPERIMENTAL
Intervention: Pregnant women (once-sampled)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Pregnant women (multisampled)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nonpregnant women
Number of subjects: 118
Study: 2156476

Group type: EXPERIMENTAL
Intervention: Ganciclovir, 2.5 mg/kg body weight every 8 hours for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 396054

Group type: EXPERIMENTAL
Intervention: 3 x 20 mg/kg praziquantel
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 x 50 mg/kg praziquantel
Number of subjects: 28
Study: 30121774

Group type: COMPARATOR
Intervention: Good glycemic control (HbA1c < 6.5%, FPG < 6.1 mmol/L)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control (HbA1c < 6.5%, FPG ≥ 6.1 mmol/L or HbA1c ≥ 6.5%, FPG < 6.1 mmol/L)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Poor glycemic control (HbA1c ≥ 6.5%, FPG ≥ 6.1 mmol/L)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Good glycemic control
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Insulin-exposed group
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control with insulin exposure
Number of subjects: 1815
Study: 28501708

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 165

Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 165
Study: 25918334

Group type: EXPERIMENTAL
Intervention: Decision aid (intervention group)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1170
Study: 24641302

Group type: EXPERIMENTAL
Intervention: Electrobrasion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 0
Study: 23419401

Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 9 g in tea, taken three times daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 30
Study: 19744817

Group type: COMPARATOR
Intervention: Internet or interactive computer-based patient education programs
Number of subjects: 2374
Study: 17922350

Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individual training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Formable HPDs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Premolded HPDs
Number of subjects: 100
Study: 16172203

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 to 30 mg per day)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Perphenazine (8 to 32 mg per day)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Quetiapine (200 to 800 mg per day)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Risperidone (1.5 to 6.0 mg per day)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40 to 160 mg per day)
Number of subjects: 1493
Study: 11821268

Group type: EXPERIMENTAL
Intervention: Gonal‐F
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Puregon
Number of subjects: 812

Group type: COMPARATOR
Intervention: Repeated cycles (both Gonal‐F and Puregon)
Number of subjects: 812
Study: 10627844

Group type: EXPERIMENTAL
Intervention: High contrast (80%) optotypes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low contrast (6%) optotypes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High contrast optotypes with dioptric blur
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normal and amblyopic eyes tested at threshold
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High contrast optotypes
Number of subjects: 30
Study: 8867876

Group type: EXPERIMENTAL
Intervention: ZK 93426 (0.04 mg; 0.04 ml/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg; 1 ml)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1363719

Group type: EXPERIMENTAL
Intervention: sulglycotide + H2-antagonists
Number of subjects: 626

Group type: COMPARATOR
Intervention: sulglycotide alone
Number of subjects: 626
Study: 6094445

Group type: EXPERIMENTAL
Intervention: Cefotaxime 3 g intravenously perioperatively
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group without prophylactic antibiotics
Number of subjects: 167
Study: 29802051

Group type: COMPARATOR
Intervention: Video-based tutorial by a skilled expert (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: VR training program (Uro-Trainer) (Group B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VR-TURBT training
Number of subjects: 51
Study: 28329753

Group type: EXPERIMENTAL
Intervention: High-intensity training (twice a week for 90 min with increasing loads)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 25909233

Group type: EXPERIMENTAL
Intervention: Alcohol-Wise online alcohol prevention program
Number of subjects: 0
Study: 24108779

Group type: EXPERIMENTAL
Intervention: 0.2 ml of DTaP
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 0.5 ml of DTaP
Number of subjects: 111
Study: 21435609

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Post-procedural minimal lumen diameter
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 400
Study: 19666435

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 17554217

Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) 500 mg twice daily or 1000 mg twice daily with ritonavir 100 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-dose TPV/r
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-dose TPV/r
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 41
Study: 15132999

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - METPA (weighted metabolic score of intensity, frequency, and duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - MECHPA (sum of all ground reaction forces multiplied by duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone mass measurement in black children (girls only)
Number of subjects: 0
Study: 11181397

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole for 7 days followed by oral itraconazole solution at 200 mg twice daily for 14 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral itraconazole solution at 200 mg once daily for 14 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution at 200 mg twice daily for 14 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole for 7 days followed by oral itraconazole solution
Number of subjects: 17
Study: 1350340

Group type: EXPERIMENTAL
Intervention: Pentazocine with clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous placebo with clonidine
Number of subjects: 0
Study: 2863295

Group type: EXPERIMENTAL
Intervention: Fenoldopam 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenoldopam (various doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 10